Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatocellular Carcinoma
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
High Risk
11%
Risk Factors
11%
Hepatitis C Virus
11%
Insulin Resistance
11%
Molecular Mechanism
11%
Effective Treatment
11%
Diabetes
11%
Low Risk
11%
Cirrhosis
11%
Fibrosis
11%
Obesity
11%
Chronic Infection
11%
Alcoholic
11%
Developed Countries
11%
High Prevalence
11%
Improved Prognosis
11%
Epidemiology
11%
Chronic Hepatitis C
11%
Hepatitis B Virus
11%
Early Recognition
11%
Disease-associated
11%
Common Cancers
11%
Metformin
11%
B Hepatitis
11%
Hyperinsulinemia
11%
Metabolic Disorders
11%
New Targets
11%
Signal Alteration
11%
Non-cirrhotic
11%
Hemochromatosis
11%
Hepatic Manifestations
11%
Liver-specific
11%
Rising Incidence
11%
Risk Prognosis
11%
Alcoholic Liver Injury
11%
TNF Signaling Pathway
11%
PPARγ Agonist
11%
Cellular Lipid Metabolism
11%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Nonalcoholic Fatty Liver
100%
Tumor Necrosis Factor
11%
Chronic Hepatitis C
11%
Hepatitis C Virus
11%
Malignant Neoplasm
11%
Prevalence
11%
Infection
11%
Diabetes
11%
Fibrosis
11%
Liver Injury
11%
Liver Cirrhosis
11%
Insulin Resistance
11%
Signal Transduction
11%
Cohort Effect
11%
Hepatitis B Virus
11%
Glycon
11%
Peroxisome Proliferator Activated Receptor Gamma Agonist
11%
Lipid Metabolism
11%
Water-Electrolyte Imbalance
11%
Hemochromatosis
11%
Alcohol Liver Cirrhosis
11%
Hyperinsulinemia
11%
Pathogenesis
11%
Effective Treatment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Nonalcoholic Fatty Liver
100%
Tumor Necrosis Factor
11%
Infection
11%
Insulin Resistance
11%
Malignant Neoplasm
11%
Fibrosis
11%
Liver Cirrhosis
11%
Liver Injury
11%
Prevalence
11%
Chronic Hepatitis C
11%
Hepatitis B Virus
11%
Hyperinsulinemia
11%
Peroxisome Proliferator Activated Receptor Gamma Agonist
11%
Metformin
11%
Hepatitis C Virus
11%
Hemochromatosis
11%
Alcohol Liver Cirrhosis
11%
Lipid
11%
Metabolic Disorder
11%
Epidemiology
11%
Pathogenesis
11%
Immunology and Microbiology
Non-Alcoholic Fatty Liver Disease
100%
Prevalence
16%
Tumor Necrosis Factor
16%
Lipid Metabolism
16%
Signal Transduction
16%
Agonist
16%
Hepatitis C
16%
Hepatitis C Virus
16%
Hepatitis B Virus
16%
Insulin Resistance
16%
Infection
16%
Cohort Effect
16%
Epidemiology
16%
Cirrhosis
16%